Table 1.

NSCLC Nivolumab-treated cohort. For each patient the (i) number of cycles of nivolumab therapy performed, (ii) time of treatment failure (TTF), (iii) overall survival (OS), (iv) iRECIST classification for the radiological assessments (RA), are reported: complete response (iCR), partial response (iPR), stable disease (iSD), unconfirmed progressive disease (iUPD), confirmed progressive disease (iCPD) and hyper-progression (iHP). Patients continuing the therapy are highlighted in grey.

Subject Number	N° Cycles	TTF (Weeks)	OS (Weeks)	1 RA	2 RA	3 RA	4 RA	5 RA	6 RA	7 RA	8 RA	9 RA	10 RA	11 RA	12 RA
MetL01	4	8	10	na (HP)
MetL05	24	59	94	iSD/PR	iSD	iUPD	iCPD
MetL06	4	8	13	iUPD
MetL07	84	186+	193+	iPR	iPR	iPR	iPR	iPR	iPR	iPR	iPR	iPR	iPR	iPR	iPR
MetL09	19	38	67	iSD	iUPD	iUPD	iCPD
MetL10	10	18	20	iSD	iSD
MetL11	9	23	60	iUPD	iCPD
MetL12	23	45	60	iUPD	iPR	iSD	iPD
MetL13	29	140+	167+	iUPD	iUPD	iPR	iPR	iUPD	iUPD	iPR	iSD	iSD	iSD
MetL15	2	2	5	na (HP)
MetL17	19	41	103	iUPD	iUPD	iCPD
MetL19	27	66	104	iUPD	iUPD	iSD	iSD	iCPD
MetL20	4	6	8	na (HP)
MetL24	6	10	48	iPD
MetL26	6	10	36	iPD
MetL29	3	5	60	na (HP)
MetL30	2	4	14	HP
MetL32	8	17	19	iUPD
MetL33	13	35	41	iSD	iSD	iUPD	iCPD
MetL34	2	2	4	na (HP)
MetL36	8	16	21	iUPD	iCPD
MetL37	17	38	44	iUPD	iUPD	iCPD
MetL39	4	7	14	iUPD
MetL40	47	99+	102+	iPR	iPR	iPR	iPR	iPR	iPR	iPR
MetL41	6	12	23	iUPD	iCPD
MetL42	18	39	100+	iUPD	iUPD	iUPD	iCPD
MetL44	11	20	92+	iUPD	iCPD
MetL45	8	15	19	iUPD	iCPD
MetL48	19	37	75+	iUPD	iPR	iPD
MetL49	1	1	1	na (HP)
MetL50	35	70+	73+	iPR	iPR	iPR	iPR
MetL52	29	58+	70+	iUPD	iUPD	iUPD	iUPD	iUPD	iCPD
MetL53	19	54+	59+	iPR	iPR	iSD	iPR
MetL57	7	15	52+	iUPD	iCPD